A Retrospective, Observational, Open-label study to evaluate the safety and efficacy of Ustekinumab Intravenous Induction treatment in Patients with Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents
Latest Information Update: 20 Dec 2018
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
Most Recent Events
- 20 Dec 2018 New trial record
- 24 Oct 2018 Results presented at the 26th United European Gastroenterology Week